Trial Profile
Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Jun 2022
Price :
$35
*
At a glance
- Drugs Measles mumps and rubella virus vaccine-(Priorix) (Primary) ; DTaP poliovirus vaccine; Measles mumps and rubella virus vaccine; MMR-varicella zoster virus vaccine; Varicella zoster virus vaccine live
- Indications Diphtheria; Herpes zoster; Measles; Mumps; Pertussis; Poliomyelitis; Rubella; Tetanus
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline; GSK
- 06 Jun 2022 According a GlaxoSmithKline media release, company announced that the US Food and Drug Administration (FDA) has approved PRIORIX (Measles, Mumps and Rubella Vaccine, Live) for active immunization for the prevention of measles, mumps and rubella (MMR) in individuals 12 months of age and older.
- 20 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 May 2015 Planned End Date changed from 1 Oct 2015 to 1 Nov 2015, according to to ClinicalTrials.gov record.